The study focuses on evaluating the effectiveness of intravesical administration of hyaluronic acid (INSTYLAN) in reducing the frequency of recurrent urinary tract infections (UTIs) and improving symptoms in women. Hyaluronic acid helps restore the protective urothelial barrier, reducing bacterial adhesion and inflammation. The study included 24 female patients who received INSTYLAN and 20 women in the control group (fosfomycin). The results showed a significant reduction in the frequency of UTIs in the INSTYLAN group, no serious side effects, and improved patient satisfaction.
SELF-MEDICATION CAN BE HARMFUL TO YOUR HEALTH
Before using the product offered on this information resource, it is recommended to consult your doctor and read the instructions.
Information about medical products for the professional work of health professionals. INSTYLAN (INSTILAN) 0.16% colorless, transparent, viscous gel of hyaluronic acid of non-animal origin, sterile, physiological pH.
INSTYLAN 0,16% approved as Class ІІa medical devices. EU Declaration of Conformity. Registration number: DD 60107286 0001 Manufacturer: Diaco Biofarmaceutici S.R.L. Via Flavia 124, 34147, Trieste, Italy. E-mail: info@diaco.it. www.diaco.it.
